Clinical trials: Tirzepatide
Obesity
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Many people who have bariatric (weight-loss) surgery do not lose as much weight as expected, or they regain weight over time. This study will test whether a medicine called tirzepatide can help these patients lose more weight and…
- Trial name
- TirBaS (NCT07829198)
- Testing
- Tirzepatide
- Where
- 3 sites in Portugal
- Volunteers
- 70 people
- Sponsor
- Universidade do Porto
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Healthy
Study of Tirzepatide in Healthy Participants
The purpose of this study is to look at how much tirzepatide gets into the bloodstream and how long the body takes to get rid of it. This study will involve a single dose of 14C radiolabelled tirzepatide.
- Trial name
- NCT04311424
- Testing
- 14C Tirzepatide
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema.
- Trial name
- REIMAGINE 5 (NCT06534411)
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 163 sites in United States, Argentina and 12 more
- Volunteers
- 1,023 people
- Sponsor
- Novo Nordisk A/S
Cannabis Use Disorder
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
- Trial name
- NCT07468552
- Testing
- Tirzepatide
- Volunteers
- 100 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Alcohol Use Disorder (AUD)
Study of Tirzepatide for Recovery and Alcohol Use Management
This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10).
- Trial name
- STREAM (NCT06727331)
- Testing
- Tirzepatide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Sarcoma,Soft Tissue
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic.
- Trial name
- NCT07874828
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Type 1 Diabetes Mellitus, Overweight and Obesity
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks.
- Trial name
- TZP-T1D (NCT06180616)
- Testing
- Tirzepatide
- Volunteers
- 40 people
- Sponsor
- Royal North Shore Hospital
Nonalcoholic Steatohepatitis
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
- Trial name
- SYNERGY-NASH (NCT04166773)
- Testing
- Tirzepatide
- Where
- 112 sites in United States, Belgium and 8 more
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Aging, Obesity & Overweight
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2…
- Trial name
- NCT07444073
- Testing
- Not applicable. This is an observational study.
- Where
- 2 sites in Singapore
- Volunteers
- 440 people
- Sponsor
- National University of Singapore
Obesity
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in…
- Trial name
- NCT07099742
- Testing
- Tirzepatide, Life Style Modification
- Where
- 3 sites in Bangladesh
- Volunteers
- 364 people
- Sponsor
- Dr. Md. Alimur Reza
Obesity and Obesity-related Medical Conditions
Efficacy and Safety of Tirzepatide for Weight Management
The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes.
- Trial name
- NCT06918405
- Testing
- Tirzepatide
- Where
- Bangladesh
- Volunteers
- 440 people
- Sponsor
- Chittagong Medical College
Diabetes Mellitus, Type 2
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a…
- Trial name
- NCT03951753
- Testing
- Tirzepatide, Semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
This is a randomized controlled trial to compare the effect of AI-assisted multi-domain lifestyle and continued tirzepatide on body weight loss maintenance.
- Trial name
- NCT07555730
- Testing
- AI assisted multi-domain lifestyle intervention, Tirzepatide
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Huazhong University of Science and Technology
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes.
- Trial name
- SURPASS-2 (NCT03987919)
- Testing
- Tirzepatide, Semaglutide
- Where
- 127 sites in United States, Argentina and 7 more
- Volunteers
- 1,879 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-TIRZSEMA (NCT06914141)
- Testing
- Tirzepatide, Semaglutide
- Where
- United States
- Volunteers
- 28,118 people
- Sponsor
- Brigham and Women's Hospital
Overweight, Obesity
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity.
- Trial name
- NCT06916065
- Testing
- Eloralintide and Tirzepatide, Eloralintide
- Where
- 3 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eli Lilly and Company
Obesity & Overweight, Cardiometabolic Health Indicators
Tirzepatide Impact Assessment Study
This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body.
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders
- Trial name
- TIA (NCT07740291)
- Testing
- GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Obesity
A Study of BGM0504 in Participants With Obesity
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
- Trial name
- NCT06911203
- Testing
- BGM0504, Tirzepatide
- Where
- China
- Volunteers
- 96 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-4 (NCT03730662)
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 216 sites in United States, Argentina and 13 more
- Volunteers
- 2,002 people
- Sponsor
- Eli Lilly and Company